Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Human Vaccines & Immunotherapeutics|April 28, 2015
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccineAlain Luxembourg, Darron Brown, Celine Bouchard, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 14, 2020
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-upSven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, et al.
Pediatrics|June 24, 2015
Immunogenicity and Safety of a 9-Valent HPV VaccinePierre Van Damme, Sven Eric Olsson, Stanley Block, et al.
Human Vaccines & Immunotherapeutics|January 22, 2025
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studiesAnna R Giuliano, Joel M Palefsky, Stephen E Goldstone, et al.
Gynecologic Oncology|April 16, 2019
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo populationAnna R Giuliano, Elmar A Joura, Suzanne M Garland, et al.
Human Vaccines & Immunotherapeutics|July 19, 2022
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 yearsIvette Maldonado, Manuel Plata, Mauricio Gonzalez, et al.
Eclinicalmedicine|July 9, 2020
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countriesSusanne K Kjaer, Mari Nygård, Karin Sundström, et al.
The Lancet. Infectious Diseases|November 15, 2021
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trialStephen E Goldstone, Anna R Giuliano, Joel M Palefsky, et al.
Pediatrics|January 2, 2021
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV VaccineJacob Bornstein, Surita Roux, Lone Kjeld Petersen, et al.
Pediatrics|September 5, 2023
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and SafetyJaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, et al.
Pageof 7